Peptides DB
Research-centric peptide and protocol reference hub
Study 22 of 27Vosoritide literatureHormone research in paediatrics · Observational · Phase 22023

Slipped Capital Femoral Epiphysis during Vosoritide Therapy for Short Stature: A Case Series.

Vosoritide therapy may be linked to an increased risk of slipped capital femoral epiphysis in some children with genetic short stature, particularly those with Turner syndrome and Aggrecan mutations.

Read at Hormone research in paediatricsAdd to compare

Where it sits

this study against the rest of the vosoritide corpus
1
Preclinical
17
Observational · this one
0
Open-label
3
Randomised
6
Reviews

Summary and findings

This case series reports on the occurrence of slipped capital femoral epiphysis (SCFE) in five participants undergoing vosoritide therapy for genetic short stature. All participants had received treatment for more than 12 months. SCFE was observed in specific genetic subgroups, including those with Aggrecan mutations and Turner syndrome.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
2/12 participants with ACAN mutations developed SCFE.n=5Phase 22023

Abstract

The authors’ words, as Hormone research in paediatrics supplied them

<h4>Introduction</h4>Vosoritide is a C-type natriuretic peptide analog approved for treatment of children with achondroplasia with established safety and efficacy. We report slipped capital femoral epiphysis (SCFE) as a treatment-emergent serious adverse event in two prospective clinical trials of vosoritide for individuals with genetic forms of short stature.<h4>Case report</h4>We report 5 participants from two investigator-initiated, single center, phase II, prospective, open label clinical trials of vosoritide (NCT04219007 Basket trial including patients with RASopathies, Aggrecan mutations (ACAN) and NPR2 deficiency and NCT05849389 in girls with Turner syndrome) who developed SCFE. In the basket trial, SCFE was observed in 2/12 participants with ACAN mutations, 1/11 with RASopathy but not in the 7 participants with NPR2 mutations or 24 with hypochondroplasia. In the Turner syndrome trial, 2/5 participants receiving vosoritide developed SCFE. All 5 participants who developed SCFE had received >12 months of treatment and presented with the rare valgus type of SCFE.<h4>Conclusion</h4>Vosoritide treatment may be associated with a higher risk of SCFE in some individuals with genetic forms of short stature such as Turner syndrome and Aggrecan mutations. The causal mechanisms and contributory factors to the predisposition for valgus deformities noted with vosoritide therapy in children with these genetic conditions warrant further study.

Background

This paper addresses the potential adverse effects of vosoritide, a C-type natriuretic peptide analog, in children with genetic short stature. Prior knowledge indicated that vosoritide is approved for treating achondroplasia, with established safety and efficacy. This study is significant as it highlights a serious adverse event, SCFE, that may be associated with the treatment.

Methods

The study is a case series derived from two investigator-initiated, single-center, phase II, prospective, open-label clinical trials. The population included participants with genetic forms of short stature, specifically those with ACAN mutations, RASopathy, and Turner syndrome. The duration of treatment was greater than 12 months, but specific dosing information is not reported in the abstract.

Results

In total, SCFE was reported in 5 participants across the trials. Specifically, SCFE was observed in 2 out of 12 participants with ACAN mutations and 1 out of 11 with RASopathy in the basket trial, while 2 out of 5 participants in the Turner syndrome trial also developed SCFE. All cases presented with the rare valgus type of SCFE.

Interpretation

The findings suggest a potential association between vosoritide therapy and an increased risk of SCFE, particularly in individuals with specific genetic conditions. While the statistical significance of these findings is not explicitly stated, the clinical implications warrant caution. The small sample size and open-label design limit the ability to draw definitive conclusions about causality.

Key findings

  • SCFE observed in 2/12 participants with ACAN mutations in the basket trial.
  • SCFE observed in 1/11 participants with RASopathy in the basket trial.
  • SCFE not observed in 7 participants with NPR2 mutations.
  • SCFE not observed in 24 participants with hypochondroplasia.
  • SCFE observed in 2/5 participants receiving vosoritide in the Turner syndrome trial.

Limitations

  • small sample size (n=5)
  • open-label design may introduce bias
  • single-center study limits generalizability
  • no control group for comparison
  • specific dosing information not reported

Elsewhere in the Vosoritide corpus

BA Case of Inadvertent Overdose of Vosoritide Injection in a Three-Month-Old Infant With Achondroplasia.Cureus · 2026 · 0.24 mg vosoritide administered, equivalent to 53 μg/kg.HumanAA Phase 3 Trial of Vosoritide in Children with Hypochondroplasia.NEJM evidence · 2023 · n=81 · LSM difference of 2.33 cm/year between vosoritide and placebo; 95% CI, 1.85-2.82 cm/year; two-sided P<0.0001.HumanAA Phase 3 Trial of Vosoritide in Children with Hypochondroplasia.NEJM evidence · 2023 · n=81 · LSM difference of 2.33 cm/year between vosoritide and placebo, 95% CI 1.85-2.82 cm/year, two-sided P<0.0001.HumanBPerceived Impact of Vosoritide on Health-Related Quality of Life in Children with Selected Genetic Causes of Short Stature: A Qualitative Study of Children and Caregivers.Hormone research in paediatrics · 2026 · n=21 · 74% of caregivers and 100% of children reported changes in daily activities.HumanDFrom Small Data to Big Decisions: How Clinical Pharmacology Shapes Rare Disease Development.Journal of clinical pharmacology · 2026reviewBReal-World Evidence on the Effectiveness and Safety of Vosoritide in Latin American Patients With Achondroplasia (EVOLAC).American journal of medical genetics. Part A · 2023 · n=52 · Height Z-scores increased from 0.33 to 1.58 between 6 to 36 months, p<0.001 to p<0.05.Human